An emergency contraceptive manufactured in Europe will come with a new label in 2014, warning that the pill may not be effective for women over a certain weight.
The same may be true for emergency contraceptives in the United States.
French manufacturer HRA Pharma was conducting research on another topic related to its emergency contraceptive Norlevo when scientists realized there was “a clear impact of weight” on the drug’s effectiveness, CEO Erin Gainer said.
HRA Pharma scientists discovered Norlevo began losing its effectiveness when women reach about 75 kilograms, or 165 pounds, Gainer said, and showed an “absence of effectiveness” at about 80 kilograms, or about 176 pounds.
“We felt it was our ethical duty … to report those results to our health authorities here in Europe,” Gainer said.